190 related articles for article (PubMed ID: 23960448)
1. Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
Park J; Song JH; Park DA; Lee JS; Lee SD; Oh YM
J Korean Med Sci; 2013 Aug; 28(8):1200-6. PubMed ID: 23960448
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
He B; Zhang F; Li X; Tang C; Lin G; Du J; Jin H
Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
4. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Maxey DM; Ivy DD; Ogawa MT; Feinstein JA
Pediatr Cardiol; 2013 Oct; 34(7):1628-36. PubMed ID: 23532466
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
[TBL] [Abstract][Full Text] [Related]
6. Bosentan for the treatment of portopulmonary hypertension.
Tempe DK; Datt V; Datta D
Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
[No Abstract] [Full Text] [Related]
7. Pulmonary arterial hypertension: combination therapy in the modern management era.
Sitbon O
Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
[No Abstract] [Full Text] [Related]
8. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Hoeper MM
Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
[No Abstract] [Full Text] [Related]
9. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of secondary pulmonary hypertension.
Maloney JP
Curr Opin Pulm Med; 2003 Mar; 9(2):139-43. PubMed ID: 12574694
[TBL] [Abstract][Full Text] [Related]
11. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
12. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of targeted therapies for pulmonary hypertension in children.
Roldan T; Deiros L; Romero JA; Gutierrez-Larraya F; Herrero A; Del Cerro MJ
Pediatr Cardiol; 2014 Mar; 35(3):490-8. PubMed ID: 24141893
[TBL] [Abstract][Full Text] [Related]
15. [Bosentan and chronic thromboembolic pulmonary hypertension].
Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N
Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681
[No Abstract] [Full Text] [Related]
16. Sildenafil for pulmonary hypertension: need for evidence generation.
Shafiq N; Reddy S; Pandhi P; Manoj R; Talwar KK; Malhotra S
Int J Clin Pharmacol Ther; 2008 Dec; 46(12):644-51. PubMed ID: 19049698
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
Mittoo S; Jacob T; Craig A; Bshouty Z
Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.
Minniti CP; Machado RF; Coles WA; Sachdev V; Gladwin MT; Kato GJ
Br J Haematol; 2009 Dec; 147(5):737-43. PubMed ID: 19775299
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Krishnan U; Krishnan S; Gewitz M
Pediatr Cardiol; 2008 Nov; 29(6):1082-6. PubMed ID: 18594787
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pulmonary arterial hypertension.
Ricachinevsky CP; Amantéa SL
J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S153-65. PubMed ID: 17136291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
